Range Impact Inc · OTC:RNGE
Range Impact — Graphium Biosciences — Investor Presentation (August 2023)
17 slides from Range Impact's investor presentation, August 2023
Slide 1: Investor Presentation
y GRAPHIUM ©) BIOSCIENCES INVESTOR PRESENTATION
Slide 2: Why Graphium
WHY GRAPHIUM $20M INVESTED TO DEVELOP PROPRIETARY PLATFORM TECHNOLOGY AND 250+ PATENTED GLYCOSYLATED COMPOUNDS INITIAL FOCUS ON UNLIMITED ADDITIONAL OPPORTUNITIES FOR 250+ OTHER COMPOUNDS GLYCOSYLATED THC AWARDED ORPHAN DRUG DESIGNATION IBS ANXIETY DEPRESSION PTSD CTE POISED TO DISRUPT $20B IBD MARK
Slide 3: The Problem
THE PROBLEM INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC AND DEBILITATING DISEASE AFFECTING OVER 3 MILLION AMERICANS WITH NO KNOWN CAUSE OR CURE DISTRESSING EFFECTS PHYSICAL SOCIAL PSYCHOLOGICAL ECONOMIC DESPITE AVAILABLE TREATMENTS 1 IN 4 PATIENTS WITH IBD WILL STILL REQUIRE SURGERY 3
Slide 4: Our Solution
OUR SOLUTION OUR GLYCOSYLATED CANNABINOIDS UNLOCK THE REBALANCING EFFECTS OF THE ENDOCANNABINOID SYSTEM TO REDUCE GASTROINTESTINAL INFLAMMATION WITHOUT ANY PSYCHOACTIVITY KEY ATTRIBUTES UNIQUELY NON-PSYCHOACTIVE ACTIVATED, TARGETED RELEASE LOW DOSE, SAFE AND EFFECTIVE LOW BIOAVAILABILITY STABILIZED
Slide 5: Our Process
OUR PROCESS OUR SCIENTISTS INVENTED A NOVEL ENZYMATIC PROCESS TO COMBINE HYDROPHOBIC CANNABINOIDS WITH HYDROPHILIC GLUCOSE TO ENGINEER OUR UNIQUE CANNABINOID DRUG REACTION INPUTS: PRODUCT: CANNABINOIDS GLYCOSYLATED SUGAR CANNABINOIDS WATER ENZYMES PATENTED GLYCOSYLATION PLATFORM USES RECOMBINANT DNA
Slide 6: How It Works
HOW IT WORKS OUR GLYCOSYLATED CANNABINOID IS ACTIVATED ONLY IN THE LARGE INTESTINE, RESULTING IN A TARGETED, LOW DOSE RELEASE OF CANNABINOIDS TO REDUCE INFLAMMATION LOCALLY UNMODIFIED THC OUR PRODRUG UNIQUE CHARACTERISTICS PRODRUG ACTIVATION PREVENTION OF IBD TREATMENT OF IBD LONG-TERM DAILY USE TAB
Slide 7: Favorable Scientific Data
FAVORABLE SCIENTIFIC DATA OVER 20 ANIMAL STUDIES SUCCESSFULLY COMPLETED TO REFINE OUR DRUG CANDIDATE AND DOSING LEVELS, AND TO DE-RISK FUTURE PRECLINICAL AND CLINICAL STUDIES MULTIPLE COMPOUNDS AND FORMULATIONS $15M+ TESTED IN MOUSE, RAT, AND MONKEY STUDIES INVESTED TO DATE LEAD CANDIDATE SHOWED POS
Slide 8: Drug Portfolio
DRUG PORTFOLIO OVER 250 GLYCOSYLATED CANNABINOIDS AND ENDOCANNABINOIDS SERVE AS THE FOUNDATION FOR FUTURE GROWTH OF A BROAD AND DIVERSIFIED DRUG PROGRAM THC CBD CBDV CBN AEA DHEA GLYCOSIDES GLYCOSIDES GLYCOSIDES GLYCOSIDES GLYCOSIDES GLYCOSIDES 12 37 33 7 7 7 2AG 1AG CAPSAICIN VANILLIN CURCUMIN KAUR
Slide 9: Intellectual Property
INTELLECTUAL PROPERTY COMPREHENSIVE PATENT FILINGS TO PROTECT OUR PROPRIETARY DRUG MANUFACTURING PROCESS AND LARGE PORTFOLIO OF GLYCOSYLATED CANNABINOID DRUGS @ CANNABINOID GLYCOSIDE PRODRUGS AND METHODS OF SYNTHESIS (2016) - GRANTED @ ANTIMICROBIAL COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS O
Slide 10: Competitive Landscape
COMPETITIVE LANDSCAPE SEVERAL TREATMENT OPTIONS EXIST FOR IBD BUT ALL HAVE RISKS, UNWANTED SIDE EFFECTS, AND LIMITED DURATION OF USE DRUG PRICE/YEAR TREATMENTS FOR ACTIVE ULCERATIVE COLITIS BY CATEGORY * $0 PER PATIENT (USD) $20,000 $40,000 $60,000 $80,000 SEVERE (5%) $84,000 BIOLOGICS JAK INHIBITOR
Slide 11: Competitive Advantages
COMPETITIVE ADVANTAGES OUR PHARMACEUTICAL-GRADE CANNABINOID DRUG IS ANTICIPATED TO BE USED OVER A LONG DURATION FOR THE PREVENTION AND TREATMENT OF IBD WITHOUT SIDE EFFECTS THE ENDOCANNABINOID SYSTEM UNIQUE CHARACTERISTICS NEW THERAPEUTIC CATEGORY NON-PSYCHOACTIVE ORAL DRUG, NO NEEDLES TARGETED DELI
Slide 12: Business Model
BUSINESS MODEL ATTRACTIVE PER UNIT PROFIT POTENTIAL AND OPPORTUNITY TO GAIN VALUABLE MARKET SHARE WITH OUR NEW CLASS OF IBD TREATMENT THAT UNIQUELY TARGETS THE ENDOCANNABINOID SYSTEM UNIT ECONOMICS MARKET SHARE OF 3.0M IBD PATIENTS EST. SALES: $40,000 0.2% 0.4% 0.6% 0.8% 1.0% EST. COSTS: $32,000 ANN
Slide 13: Team
| : EDWARD FEIGHAN RICHARD CELESTE MICHAEL CAVANAUGH = RICHARD MCKILLIGAN DR.BRANDON ZIPP DR. ERICK CARLSON CHAIRMAN BOARD CEO CFO CHIEF SCIENCE SCIENTIFIC OF THE BOARD MEMBER BOARD MEMBER COUNSEL OFFICER ADVISOR REBECCA WHARTON PATRICIA MISSAL REESE FIELDS MAJ GEN JAMES HOYER BERNIE KOSAR GARY WHIT
Slide 14: Drug Development Plan
DRUG DEVELOPMENT PLAN DETAILED PLAN TO ADVANCE OUR CANNABINOID DRUG AND OBTAIN EARLY CLINICAL SAFETY DATA TO DE-RISK OUR ASSET FOR A STRATEGIC BUYER 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 BIOANALYTICAL METHOD TRANSFER / SETUP 1-DAY TOXICOLOGY STUDIES - 2 SPECIES GENOTOXICITY STUDIES - IN
Slide 15: Value Proposition
VALUE PROPOSITION SIGNIFICANT RETURN POTENTIAL FOR INVESTORS GIVEN DE-RISKED DRUG DEVELOPMENT STRATEGY, ANTICIPATED SAFETY AND EFFICACY, PATENT PROTECTION AND MARKET COMPS PRE-CLINIC PHASE 1 PHASE 2 PHASE 3 APPROVAL MARKET COMPS FOR CANNABINOID PHARMA COMPANIES: 2021: JAZZ ACQUIRES GW PHARMA FOR $7.
Slide 16: Why Graphium
WHY GRAPHIUM PROPRIETARY PLATFORM TECHNOLOGY WITH 250+ NOVEL COMPOUNDS INITIAL FOCUS ON GLYCOSYLATED THC WITH STRONG SAFETY-EFFICACY PROFILE ORPHAN DRUG DESIGNATION AWARDED ON INITIAL GLYCOSYLATED THC COMPOUND INITIAL GLYCOSYLATED THC COMPOUND POISED TO DISRUPT $20B IBD MARKET UNLIMITED ADDITIONAL O
Slide 17: Thank You
THANK YOU MICHAEL CAVANAUGH BRANDON ZIPP CEO CSO 216.543.7599 530.864.6418 200 PARK AVENUE, SUITE 400 ORANGE VILLAGE, OHIO 44122 [email protected] [email protected] LEGAL DISCLOSURE - SAFE HARBOR STATEMENT 17
Graphium Biosciences — Investor Presentation (August 2023) on 6ix